Who should not take essential phospholipids
Essential phospholipids, usually abbreviated EPL and derived from soybean, are marketed as supportive agents for the liver. They are popular among people worried about liver strain, including athletes. But like any product, they are not suitable for everyone. This editorial overview sets out who should avoid them, the main cautions, and what the evidence does and does not support.
What essential phospholipids are
Essential phospholipids are purified fats extracted mainly from soybeans, rich in a molecule called polyenylphosphatidylcholine. Phospholipids are fundamental building blocks of every cell membrane, including those of liver cells. The rationale for supplementation is that providing these molecules may help the liver repair and maintain its cell membranes, particularly when they are under stress.
In the UK and across Europe, EPL products are sold both as medicines in some countries and as food supplements. They come as capsules for oral use and, in clinical settings in some regions, as an intravenous preparation. The oral capsule form is what most consumers encounter. Their regulatory classification affects how strictly their claims and quality are controlled.
Because they are promoted for "liver support", EPL products attract people with a range of concerns, from fatty liver to the general wish to protect the liver during periods of heavy training or medication use. This broad, informal use is exactly why it is worth being clear about the situations in which these products are not appropriate.
This article focuses on contraindications and cautions. It is not an endorsement of EPL for any particular condition, and it assumes that anyone with a genuine liver problem is under medical care, where the decision to use or avoid such a product can be made properly.
Clear contraindications
The most clear-cut reason to avoid essential phospholipids is a known allergy. Because the product is derived from soybean, people with soya allergy should not take it. Preparations may also contain other allergenic components depending on the formulation, so anyone with relevant food allergies should check the ingredient list carefully and avoid the product if in doubt.
Hypersensitivity to any component of a specific product is a general contraindication that applies to EPL as to any supplement or medicine. This includes excipients and the capsule shell, which may contain substances relevant to particular dietary or allergy needs. The product information for the specific brand is the authoritative source.
Intravenous forms, used only in clinical settings, carry their own specific contraindications and are not relevant to self-selected consumer use. Any parenteral product is administered by healthcare professionals who apply those restrictions. For the general reader, the oral capsule and its allergy-related contraindications are what matter.
| Situation | Status | Reason |
|---|---|---|
| Soya allergy | Avoid | EPL is soy-derived |
| Hypersensitivity to any ingredient | Avoid | Risk of allergic reaction |
| Children (without medical advice) | Caution / avoid | Limited data; follow product labelling |
| Undiagnosed liver symptoms | See a doctor first | Symptoms need assessment, not self-treatment |
Beyond allergy, the firmest piece of advice is directed at people with undiagnosed liver symptoms. Jaundice, persistent abdominal pain, dark urine or marked fatigue are signals that require medical assessment, not a self-selected supplement. Reaching for EPL in that situation risks delaying proper diagnosis.
Groups who should be cautious
Pregnant and breastfeeding women are a group for whom caution is standard with most supplements, including EPL, simply because the safety data in these populations are limited. The sensible default is to avoid non-essential supplements during pregnancy and lactation unless a clinician has advised otherwise for a specific reason.
Children and adolescents are another group where restraint is appropriate. Product labelling often specifies a minimum age, and there is little evidence to support routine use in young people. Growing bodies and limited safety data together argue for avoiding casual supplementation in this group.
People with existing, diagnosed liver disease should use EPL only within a treatment plan agreed with their hepatologist or GP. The temptation to add "liver support" supplements to serious liver conditions is understandable, but such decisions should be medical, because the wrong assumption — that a supplement is doing the work — can lead to neglect of effective treatment.
Finally, anyone taking multiple medicines, or with complex health problems, should discuss any new supplement with a pharmacist. EPL is generally regarded as low-risk, but "generally low-risk" is not the same as "safe for everyone", and a brief conversation with a pharmacist can catch the exceptions.
Interactions and practical concerns
Essential phospholipids are not known for major, dangerous drug interactions, which is part of their appeal. Nonetheless, the absence of a well-documented interaction is not a guarantee, especially given that supplement research is generally less rigorous than drug research. People on anticoagulants, immunosuppressants or other narrow-margin medicines should still mention the supplement to their clinician.
A more subtle concern is the false reassurance an "organ protector" can provide. Some people take EPL in the belief that it offsets the liver strain of other substances, including hepatotoxic drugs or heavy alcohol use. The evidence does not support the idea that a phospholipid supplement meaningfully protects the liver against such insults, and relying on it could encourage riskier behaviour.
- Not a licence to continue alcohol excess or hepatotoxic drug use.
- Tell your pharmacist if you take narrow-margin medicines.
- Check the label for allergens and age restrictions.
- Stop and seek advice if any allergic symptoms appear.
Quality is another practical matter. As with all supplements, products vary in purity and in whether they contain what the label claims. Choosing products from reputable manufacturers that comply with UK regulations reduces, though does not eliminate, this uncertainty.
Allergic reactions, though uncommon, are the main acute safety concern. Signs such as rash, itching, swelling or difficulty breathing require immediate medical attention and discontinuation. Given the soy origin, this risk is concentrated in people with soya sensitivity.
What the evidence actually supports
The clinical evidence for essential phospholipids is mixed and often of modest quality. Some studies, particularly from regions where EPL is used as a medicine, report benefits in conditions such as non-alcoholic fatty liver disease, including modest improvements in liver enzymes and ultrasound findings. Other analyses are more cautious, noting methodological limitations.
Importantly, the headline conditions that damage the liver — viral hepatitis, alcohol-related liver disease, metabolic fatty liver — have specific, evidence-based treatments: antiviral therapy, alcohol cessation, weight management and control of metabolic risk factors. EPL, at best, is adjunctive; it is not a substitute for addressing the underlying cause.
For a healthy person with no liver disease, there is little evidence that EPL provides a meaningful benefit, and the most honest position is that it is unlikely to help and, in those without allergy, unlikely to harm. That modest profile is precisely why the question of "who should not take it" comes down mostly to allergy, pregnancy, childhood and undiagnosed symptoms.
The broader lesson is that "liver support" supplements should not displace the measures that genuinely protect the liver: moderating alcohol, maintaining a healthy weight, vaccination against hepatitis where appropriate, and caution with hepatotoxic substances. These interventions have strong evidence; a phospholipid capsule does not replace them.
Conclusions of the editorial team
Essential phospholipids are a low-risk supplement for most healthy adults, but they are not for everyone. The clearest group to avoid them is people with soya allergy, followed by those with undiagnosed liver symptoms who need assessment rather than self-treatment, and by pregnant women, children and anyone with serious liver disease outside a medical plan.
The bigger point is that EPL should never be used as a shield that justifies risky behaviour, nor as a replacement for the measures that actually protect the liver. Its evidence base is modest, and its proper role is at most a minor adjunct.
Readers may also find our material on how to read liver blood tests, on evidence-based ways to protect the liver, and on why some oral drugs strain the liver useful alongside this piece.
References
- Gundermann KJ, Kuenker A, Kuntz E, et al. Activity of essential phospholipids from soybean in liver diseases. Pharmacol Rep. 2011;63(3):643–659.
- Dajani AI, Popovic B. Essential phospholipids for nonalcoholic fatty liver disease. World J Clin Cases. 2020;8(21):5235–5249.
- European Association for the Study of the Liver. EASL clinical practice guidelines on non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402.
- National Institute for Health and Care Excellence. Non-alcoholic fatty liver disease: assessment and management (NG49). London: NICE; 2016.
- Food Standards Agency. Food supplements: guidance for consumers. London: FSA; 2023.
